<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=After_The_World_And_Amiloride_Clash</id>
		<title>After The World And Amiloride Clash - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=After_The_World_And_Amiloride_Clash"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=After_The_World_And_Amiloride_Clash&amp;action=history"/>
		<updated>2026-05-14T14:18:02Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=After_The_World_And_Amiloride_Clash&amp;diff=117372&amp;oldid=prev</id>
		<title>Camel2park: Створена сторінка: 012) [10]. In one study of 18 XDR-TB patients, 60.9% had received previous treatment under DOT strategy (P?=?0.005) [21]. Eker et?al. and Murase et?al. also rep...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=After_The_World_And_Amiloride_Clash&amp;diff=117372&amp;oldid=prev"/>
				<updated>2016-11-26T08:21:34Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: 012) [10]. In one study of 18 XDR-TB patients, 60.9% had received previous treatment under DOT strategy (P?=?0.005) [21]. Eker et?al. and Murase et?al. also rep...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;012) [10]. In one study of 18 XDR-TB patients, 60.9% had received previous treatment under DOT strategy (P?=?0.005) [21]. Eker et?al. and Murase et?al. also reported one case with previous TB treatment under DOT [11, 20], and Shah et?al. also reported 28 and 30 patients under complete or partial DOT, respectively [9]. In other case report from Burkina Faso, patient one had DOT during the first 2 months of standard therapy, and patient two had previous diagnosis of MDR-TB and had 13 months of DOT therapy of SLID [28]. In South Africa, most XDR patients had no previous TB diagnosis, but it may reflect [http://www.selleckchem.com/products/PLX-4032.html learn more] lack of reporting or high chances of nosocomial transmission [10]. In another study conducted in Tugela Ferry, 69% of patients had previous TB treatment, with 56% on the past year. More than half of the patients (57%) had been hospitalized in the previous 2 years [7]. Many potential factors might contribute to treatment failure, the most relevant being male gender and HIV coinfection [11]. Reported factors for treatment non-compliance among XDR-TB patients were alcoholism (10.1%), drug addiction (42%) or both (47.8%) [34]. The term pre-XDR-TB has been introduced recently, and is defined as resistance to rifampicin, isoniazid and either to a fluoroquinolone or a SLID [21]. A higher proportion of such patients were found in South Africa [26, 35]. Accordingly to Kim, 11.3% (n?=?159) had ofloxacin-resistant pre-XDR-TB, and 8.3% (n?=?117) [https://en.wikipedia.org/wiki/Amiloride Amiloride] had SLID-resistant pre-XDR-TB. A previous history of treatment with SLID was more common in patients with XDR-TB (35.6%) and ofloxacin-resistant pre-XDR-TB (32%), P?[http://www.selleckchem.com/products/INCB18424.html Ruxolitinib price] much higher proportion of XDR-TB cases (58.4%) comparing with others conducted in the same country (24% or 6%), which may represent the local epidemic specificities of Tugela Ferry [7, 16, 25]. The same succeeds in the study. This may be explained by the fact that first represent a epidemic outbreak in this region and the latest patients were selected from a referral hospital [25]. Identifying the risk factors for the development of XDR-TB are of paramount importance to understand XDR-TB, and to the effectiveness of TB control strategies, and may have prognostic relevance; as stated by Kim et?al.&lt;/div&gt;</summary>
		<author><name>Camel2park</name></author>	</entry>

	</feed>